Positive Phase 3 HERIZON-GEA-01 results for Ziihera (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GI Up to $440.0 million in milestone ...
The Ministery of Food and Drug Safety has authorized domestic use of a new anticancer drug for patients with rare ovarian cancer who have limited treatment options. It is expected to offer a new ...
Results of a study led by researchers at Roswell Park Comprehensive Cancer Center show that combining two types of immunotherapy—engineered T cells that secrete bispecific T cell engagers (BiTEs) and ...
GEA-01 results for Ziihera® (zanidatamab-hrii) in first-line HER2-positive (HER2+) gastroesophageal adenocarcinoma (GEA) presented at ASCO GIUp to $440.0 million in milestone payments eligible to be e ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback